TOI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oncology Institute Inc (TOI) does not present a strong buy opportunity at the moment for a beginner investor with a long-term strategy. Despite positive developments such as the company's first profitable quarter and raised analyst price targets, the financial performance remains weak with negative net income and EPS. Additionally, hedge funds are selling aggressively, and there is no significant insider or congressional trading activity to indicate confidence. The technical indicators and options data also do not signal a strong entry point currently.
The MACD is positive and expanding (0.0326), suggesting bullish momentum. However, RSI at 79.102 is in the neutral zone, and moving averages are converging, indicating no clear trend. The stock is trading near resistance levels (R1: 3.508, R2: 3.661), which could limit upside potential in the short term.
Revenue increased by 41.58% YoY, and management reiterated strong 2026 guidance of $630M-$650M revenue. Analysts have raised price targets, signaling confidence in the company's growth potential.
Hedge funds are aggressively selling, with a 47487.34% increase in selling activity over the last quarter. Financial performance is weak, with a net income drop of -40.63% YoY and EPS down -57.14% YoY. No recent news, insider activity, or congressional trading data to support a buy decision.
In Q4 2025, revenue grew to $141.96M (+41.58% YoY), but net income dropped to -$6.43M (-40.63% YoY), and EPS fell to -0.06 (-57.14% YoY). Gross margin improved to 14.89% (+15.52% YoY), but overall profitability remains a concern.
B. Riley raised the price target from $6 to $8 and maintains a Buy rating, citing the company's profitable quarter and strong revenue guidance. However, the stock's near-term performance remains uncertain due to weak financial metrics and selling pressure from hedge funds.
